We are live on ! Find out more
UTHR icon

United Therapeutics

415 hedge funds and large institutions have $9.34B invested in United Therapeutics in 2021 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 138 increasing their positions, 160 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more call options, than puts

Call options by funds: $46.1M | Put options by funds: $18.8M

14% more capital invested

Capital invested by funds: $8.17B → $9.34B (+$1.17B)

13% more funds holding in top 10

Funds holding in top 10: 1517 (+2)

7% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 58

2.56% less ownership

Funds ownership: 98.56%96% (-2.6%)

3% less funds holding

Funds holding: 426415 (-11)

14% less repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 160

Holders
415
Holders Change
-11
Holders Change %
-2.58%
% of All Funds
6.37%
Holding in Top 10
17
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+13.33%
% of All Funds
0.26%
New
54
Increased
138
Reduced
160
Closed
58
Calls
$46.1M
Puts
$18.8M
Net Calls
+$27.3M
Net Calls Change
+$54.9M

UTHR Hedge Fund Activity: Q4 2021 in Review

415 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2021, worth a combined $9.34B — up 14% from $8.17B a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of UTHR and 54 opened new positions — a net loss of 4 holders — while 160 trimmed existing stakes and 138 added.

The largest buyer was Wellington Management Group, adding an estimated $189M. The largest seller was Deutsche Bank, cutting an estimated $162M.

  • 415 institutional investors held United Therapeutics (UTHR) as of Q4 2021, down from 426 in Q3 2021.
  • Funds reported $9.34B of United Therapeutics stock for Q4 2021, up 14% quarter-over-quarter.
  • 54 funds opened new United Therapeutics positions in Q4 2021 and 58 closed out, a net change of -4 holders.
  • The largest United Therapeutics buyer in Q4 2021 was Wellington Management Group, an estimated $189M added.
  • The largest United Therapeutics seller in Q4 2021 was Deutsche Bank, an estimated $162M sold.

Based on aggregated 13F filings for Q4 2021.